Orthogen LLC was spun off from its corporate parent, BioLok International, Inc, in October 2007. As a BioLok division, Orthogen previously developed the LaserLok™ line of dental implants and calcium sulfate-based bone graft materials. The new company retains intellectual property rights for new generations of bone graft products, bioreactors, “smart” transcutaneous prostheses, orthopedic implants, cardiac stents and intraocular lenses. Orthogen is currently researching and scaling up these technologies.
In the near term, Orthogen LLC is developing and marketing a new line of completely resorbable synthetic bone graft products for dental applications trade-named DentoGen™. Presently, Orthogen is clinically testing a novel, patented nanocomposite bone graft material, DentoGen-CR, that undergoes controlled degradation in the body and stimulates bone regeneration as it degrades. A first generation bone graft material, DentoGen™, was launched earlier in 2008.
|
|